Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.

Valgimigli M., Bueno H., Byrne RA., Collet J-P., Costa F., Jeppsson A., Jüni P., Kastrati A., Kolh P., Mauri L., Montalescot G., Neumann F-J., Petricevic M., Roffi M., Steg PG., Windecker S., Zamorano JL., Levine GN., ESC Scientific Document Group .

More information Original publication

DOI

10.1093/ejcts/ezx334

Type

Journal article

Publication Date

2018-01-01T00:00:00+00:00

Volume

53

Pages

34 - 78

Total pages

44

Keywords

Acute coronary syndromes, Aspirin, Bleeding, Clopidogrel, Coronary artery bypass grafting, Coronary artery disease, DAPT score, Drug-eluting stents, Dual antiplatelet therapy, Guidelines, Myocardial infarction, Non-cardiac surgery, Oral anticoagulant, PRECISE-DAPT score, Percutaneous coronary intervention, Prasugrel, Recommendation, Revascularization, Risk stratification, Stable angina, Stable coronary artery disease, Stent thrombosis, Stents, Ticagrelor, Triple therapy, Cardiology, Coronary Artery Disease, Europe, Humans, Platelet Aggregation Inhibitors, Societies, Medical